Lamontagne et al1 present findings in this issue of JAMA Internal Medicine from a study focused on the epidemiology, management patterns, and clinical consequences of nonleg venous thrombosis. This prospective cohort study is nested in a large international trial (Prophylaxis for Thromboembolism in Critical Care Trial, aka, PROTECT) randomizing medical-surgical intensive care unit (ICU) patients to either unfractionated heparin or dalteparin for thromboprophylaxis. Of the 3746 patients, 84 (2.2%) experienced a total of 145 nonleg venous thromboses. Most thrombotic segments (94.5%) occurred in the upper extremity, and most thrombi occurred in the more clinically important deep vein distribution.
Maynard G. Upper Extremity Deep Vein ThrombosisA Call to Arms. JAMA Intern Med. 2014;174(5):696-698. doi:10.1001/jamainternmed.2013.14014